STOCK TITAN

COGNETIVITY NEUROSCIENCES - $CGNSF STOCK NEWS

Welcome to our dedicated page for COGNETIVITY NEUROSCIENCES news (Ticker: $CGNSF), a resource for investors and traders seeking the latest updates and insights on COGNETIVITY NEUROSCIENCES stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect COGNETIVITY NEUROSCIENCES's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of COGNETIVITY NEUROSCIENCES's position in the market.

Rhea-AI Summary
Cognetivity's CognICA technology shows cost-efficiency and improved clinical outcomes compared to traditional cognitive assessment tools, potentially saving over £40 million per year in healthcare costs. The tool's cost-effectiveness is demonstrated in both primary care and specialized memory clinic settings, with quality-of-life improvements for patients. The broader financial benefits of incorporating CognICA into clinical practice could be substantial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.22%
Tags
none
-
Rhea-AI Summary
Cognetivity announces collaboration with UC Health to improve early detection of cognitive impairment in the USA
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
partnership
-
Rhea-AI Summary
Cognetivity Neurosciences announces collaboration with Mediclinic Group to revolutionize brain health diagnosis and care in the UAE.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Cognetivity partners with No Fear Counselling to provide advanced mental health tools
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
partnership AI
-
Rhea-AI Summary
Cognetivity Neurosciences wins Best AI Product in Healthcare award at CogX Festival
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.1%
Tags
AI
-
Rhea-AI Summary
Cognetivity Neurosciences shortlisted for Most Innovative AI Product in Healthcare award at CogX Festival.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.79%
Tags
AI
Rhea-AI Summary
Cognetivity's ADePT Study demonstrates 93% sensitivity in detecting cognitive impairment in early-stage Alzheimer's disease, outperforming current tests. CognICA's ease of use and speed enable wide-scale deployment. Urgent need for CognICA to be used in primary care for effective treatment with new drugs. Positive outlook for Cognetivity's unique ability to solve the issue of reliable early detection and monitoring in the global battle against Alzheimer's disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
AI
-
-
Rhea-AI Summary
Cognetivity Neurosciences' AI technology, CognICA, is set to play a pivotal role in the early detection and monitoring of Alzheimer's disease following FDA approval of Eisai's Leqembi. The approval means that Leqembi will now be covered for all patients, potentially benefiting millions of sufferers worldwide. CognICA has already demonstrated its effectiveness in detecting early-stage cognitive impairment and monitoring cognitive function in Alzheimer's patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.76%
Tags
partnership AI
COGNETIVITY NEUROSCIENCES

OTC:CGNSF

CGNSF Rankings

CGNSF Stock Data

1.81M
77.65M
13.5%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
Vancouver